Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients' Evidence From Latin America.
Martínez-Cordero H, Peña C, Schutz NP, Bove V, Villano F, Beltran C, Donoso J, López-Vidal H, Roa Salinas MA, Soto P, Ochoa P, Duarte P, Remaggi G, Corzo A, Shanley C, Lopresti S, Orlando S, Verri V, Quiroga LD, Fantl D, Ramirez J, Ospina-Idárraga A, Idrobo H, Quintero G, Gomez R, Cantú-Martínez O, Gomez-Almaguer D, Ruiz-Arguelles GJ, Galvez-Cárdenas KM, Salazar LA, Novoa-Caicedo I, Fuentes-Lacouture MC, Spirko P, Arbeláez MI, Pereira M, Valdes J, Vasquez J, von Glasenapp A, Riva E; GELAMM (Grupo de Estudio Latinoamericano de Mieloma Múltiple). Martínez-Cordero H, et al. Among authors: schutz np. JCO Glob Oncol. 2023 Sep;9:e2300182. doi: 10.1200/GO.23.00182. JCO Glob Oncol. 2023. PMID: 38060975 Free PMC article.
Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study.
Peña C, Riva E, Schutz N, Tarín-Arzaga L, Martínez-Cordero H, Bove V, Osorio R, Chandía M, Beltrán C, Schulz J, Cardemil D, Contreras C, Vergara CG, Donoso J, Espinoza M, La Rocca G, López-Vidal H, León P, Rojas Hopkins C, Soto P, Aranda S, Torres V, Roa M, Ochoa P, Duarte PJ, Remaggi G, Yantorno S, Corzo A, Zabaljauregui S, Shanley C, Lopresti S, Orlando S, Verri V, Quiroga L, García C, Fernández V, Ramirez J, Molina A, Pacheco M, Mite A, Reyes I, Sabando B, Ramírez F, Sossa C, Abello V, Idrobo H, Galvez Cardenas KM, Saavedra D, Quintero G, Gazitúa R, Gaviria L, Gomez R, Osuna M, Henao-Uribe A, Cantú-Martínez O, Gómez-Almaguer D, García-Navarrete YI, Cruz-Mora A, Cantero-Fortiz Y, Ruiz-Argüelles GJ, Fantl D. Peña C, et al. Leuk Lymphoma. 2020 Dec;61(13):3112-3119. doi: 10.1080/10428194.2020.1804558. Epub 2020 Aug 26. Leuk Lymphoma. 2020. PMID: 32844699
Epidemiological and clinical characteristics and outcome of monoclonal gammopathy of renal significance-related lesions in Latin America.
Peña C, Schutz NP, Riva E, Valjalo R, Majlis A, López-Vidal H, Lois V, Zamora D, Ochoa P, Shanley C, Gonzalez JT, Fantl D, Correa G, Ramirez J, Mur P, Silva G, Verri V, Rojas C, Escobar K, Glavic G, Méndez GP; Grupo de estudio latinoamericano de mieloma múltiple (GELAMM). Peña C, et al. Among authors: schutz np. Nephrology (Carlton). 2020 Jun;25(6):442-449. doi: 10.1111/nep.13685. Epub 2019 Dec 19. Nephrology (Carlton). 2020. PMID: 31825549
Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
Schütz NP, Ochoa P, Duarte P, Remaggi G, Yantorno S, Corzo A, Zabaljauregui S, Shanley C, Lopresti S, Orlando S, Verri V, Quiroga L, García CA, Fernández V, Fantl D. Schütz NP, et al. Hematol Oncol. 2020 Aug;38(3):363-371. doi: 10.1002/hon.2729. Epub 2020 Apr 20. Hematol Oncol. 2020. PMID: 32196120
Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from grupo argentino de mieloma múltiple.
Duarte PJ, Schutz NP, Ochoa P, Yantorno S, Orlando S, Lopresti S, Zabaljauregui S, Aizpurua F, Shanley C, Giannini E, Garate G, Foncuberta C, Milone J, Riveros D, Fantl D. Duarte PJ, et al. Among authors: schutz np. Expert Rev Hematol. 2021 Mar;14(3):315-322. doi: 10.1080/17474086.2021.1886073. Epub 2021 Mar 1. Expert Rev Hematol. 2021. PMID: 33541156
Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group.
Peña C, Riva E, Schutz N, Ramírez A, Vásquez J, Del Carpio D, Seehaus C, Ochoa P, Vengoa R, Duarte P, Martínez-Cordero H, Figueredo Y, Ríos RO, Ramírez J, Bove V, Roa M, Russo M, Espinoza M, Rodriguez G, Remaggi G, Enciso ME, Chandía M, Fantl D; Grupo de Estudio Latinoamericano de Mieloma Múltiple (GELAMM). Peña C, et al. Leuk Lymphoma. 2023 Apr;64(4):816-821. doi: 10.1080/10428194.2023.2171266. Epub 2023 Jan 25. Leuk Lymphoma. 2023. PMID: 36695519
Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results of a Latin American survey. GELAMM (Grupo de Estudio Latino Americano de Mieloma Múltiple).
Riva E, Schütz N, Peña C, Ruiz-Argüelles G, Hopkins CR, Bove V, Villano F, Andino L, Suárez L, Martínez H, Navarro J, López-Vidal H, Da Costa O, Pineda MR, Rubio Y, Ramirez J, Choque J, Fantl D. Riva E, et al. Ann Hematol. 2020 May;99(5):1025-1030. doi: 10.1007/s00277-020-03983-x. Epub 2020 Mar 10. Ann Hematol. 2020. PMID: 32157420 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 36164146
29 results